Myung In Pharmaceutical LTD. (KRX:317450)

South Korea flag South Korea · Delayed Price · Currency is KRW
62,400
+300 (0.48%)
At close: Feb 24, 2026
Market Cap946.08B
Revenue (ttm)283.31B +16.9%
Net Income72.18B -3.1%
EPS6,407.02 -3.7%
Shares Out14.60M
PE Ratio10.11
Forward PEn/a
Dividend1,500.00 (2.40%)
Ex-Dividend DateDec 29, 2025
Volume23,569
Average Volume58,319
Open63,000
Previous Close62,100
Day's Range62,100 - 63,300
52-Week Range57,800 - 134,500
Betan/a
RSI54.02
Earnings DateMar 31, 2026

About KRX:317450

Myung In Pharmaceutical LTD., a pharmaceutical company, manufactures ETC and OTC drugs. It offers products in the areas of thrombosis and anti-platelet, anti-hypertensive, anti-angina, anti-parkinson, anti-dementia, anti-epileptics, anti-schizophrenia, anti-depressants, adhd, anti-insomnia, gum disease treatment, gastrointestinal, cold-cough medicine, anti-fever, anti-pain, anti-inflammation agent, nutrition supplements and other pharmaceuticals. The company also provides APIs, such as benztropine mesylate, benidipine hcl, clopidogrel bisulfate... [Read more]

Industry Pharmaceutical Preparations
Founded 1985
Employees 335
Stock Exchange Korea Stock Exchange
Ticker Symbol 317450
Full Company Profile

Financial Performance

In 2024, KRX:317450's revenue was 269.43 billion, an increase of 11.18% compared to the previous year's 242.34 billion. Earnings were 68.67 billion, a decrease of -7.84%.

Financial Statements